ArticleAnnals of internal medicine2014

ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.

Oscar L Morey-Vargas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.